CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
Dexamethasonedrug
Likely dose
Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorateAI-extracted
Key inclusion· 2
  • ✓Age 18 years or older
  • ✓Symptomatic oral lichen planus with VAS sensitivity score ≥7 over the last week
Key exclusion· 4
  • ✕Already on topical or systemic steroids
  • ✕Unable to comply with study instructions
  • ✕Uncontrolled intercurrent illness or psychiatric illness/social situations limiting compliance
  • ✕VAS sensitivity score <7

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02850601
NCT02850601Phase 2Completed
CompareCT.gov

Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus

Brigham and Women's Hospital·interventional·Posted Aug 1, 2016·Updated Jun 14, 2021

In Brief

A Phase 2 clinical trial evaluating Dexamethasone for Lichen Planus. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The objective of this single center, 4-week, open label randomized, phase II study is to evaluate and characterize the tolerability and clinical effectiveness of dexamethasone 0.5mg/5ml solution in a mucoadhesive vehicle (Mucolox™) for the treatment of oral lichen planus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLichen Planus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 1, 2016
Enrollment StartFeb 7, 2017
Primary CompletionDec 19, 2019
Study CompletionDec 20, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.9 years ago

Interventions

Dexamethasonedrug

Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate